Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemOx, Bevacizumab, and Chemoradiation in Locally Advanced Pancreatic Cancer
NCT00602602Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2007
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in pancreatic cancer (PC), sponsored by Abramson Cancer Center. Primary endpoints: Response rate pre-radiation chemotherapy and bevacizumab and after 5-6 weeks of concurrent chemoradiotherapy and bevacizumab, Progression-free survival at 26 weeks and 2 more. Started Mar 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00602602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602602.